An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Many cancer therapies cause DNA damage to effectively kill proliferating tumor cells; however, a major limitation of current therapies is the emergence of resistant tumors following initial treatment. Cell cycle checkpoints are involved in the response to DNA damage and specifically prevent cell cycle progression to allow DNA repair. Tumor cells can take advantage of the G2 checkpoint to arrest following DNA damage and avoid immediate cell death. This can contribute to acquisition of drug resistance. By abrogating the G2 checkpoint arrest, it may be possible to synergistically augment tumor cell death induced by DNA damage and circumvent resistance. This requires an understanding of the molecules involved in regulating the checkpoints. Human Chk1 is a recently identified homologue of the Schizosaccharomyces pombe checkpoint kinase gene, which is required for G2 arrest in response to DNA damage. Chk1 phosphorylates the dual specificity phosphatase cdc25C on Ser-216, and this may be involved in preventing cdc25 from activating cdc2/cyclinB and initiating mitosis. To further study the role of Chk1 in G2 checkpoint control, we identified a potent and selective indolocarbazole inhibitor (SB-218078) of Chk1 kinase activity and used this compound to assess cell cycle checkpoint responses. Limited DNA damage induced by gamma-irradiation or the topoisomerase I inhibitor topotecan was used to induce G2 arrest in HeLa cells. In the presence of the Chk1 inhibitor, the cells did not arrest following gamma-irradiation or treatment with topotecan, but continued into mitosis. Abrogation of the damage-arrest checkpoint also enhanced the cytotoxicity of topoisomerase I inhibitors. These studies suggest that Chk1 activity is required for G2 arrest following DNA damage.

[1]  A. Eastman,et al.  Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[3]  H. Piwnica-Worms,et al.  A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Takahashi,et al.  UCN-01, a selective inhibitor of protein kinase C from Streptomyces. , 1987, The Journal of antibiotics.

[5]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[6]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[7]  P. O'Connor,et al.  DNA damage checkpoints: implications for cancer therapy. , 1996, Progress in cell cycle research.

[8]  C. Peng,et al.  Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. , 1997, Science.

[9]  L. Meijer.  Chemical inhibitors of cyclin-dependent kinases. , 1996, Trends in cell biology.

[10]  S. Antoku,et al.  Enhancement of X-ray cell killing in cultured mammalian cells by the protein phosphatase inhibitor calyculin A. , 1994, Cancer research.

[11]  D. Vesey,et al.  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. , 1993, Journal of medicinal chemistry.

[12]  P. Kirschmeier,et al.  Indolocarbazoles. 1. Total synthesis and protein kinase inhibiting characteristics of compounds related to K-252c. , 1993 .

[13]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[14]  F Ianzini,et al.  Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells. , 1997, International journal of radiation biology.

[15]  A. Fattaey,et al.  Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. , 1997, Progress in cell cycle research.

[16]  E. Sausville,et al.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.

[17]  A. Blasina,et al.  A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase , 1999, Current Biology.

[18]  R. Schlegel,et al.  Staurosporine overrides checkpoints for mitotic onset in BHK cells. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  C. Peng,et al.  C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[20]  A. Pardee,et al.  Mechanism by which caffeine potentiates lethality of nitrogen mustard. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Antony M. Carr,et al.  The chk1 pathway is required to prevent mitosis following cell-cycle arrest at ‘start’ , 1995, Current Biology.

[22]  M. Groudine,et al.  Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. , 1995, Cancer research.

[23]  A. Kumagai,et al.  The Xenopus Chk1 Protein Kinase Mediates a Caffeine-sensitive Pathway of Checkpoint Control in Cell-free Extracts , 1998, The Journal of cell biology.

[24]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[25]  J. Bishop,et al.  Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  N. Walworth,et al.  Association of Chk1 with 14-3-3 proteins is stimulated by DNA damage. , 1999, Genes & development.

[27]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[28]  M. Yoshida,et al.  Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. , 1991, Experimental cell research.

[29]  W. Dewey,et al.  Nuclear fragmentation and premature chromosome condensation induced by heat shock in S-phase Chinese hamster ovary cells. , 1988, Cancer research.

[30]  M. Hemling,et al.  Protein kinase C inhibitors: novel spirosesquiterpene aldehydes from a marine sponge Aka (= Siphonodictyon) coralliphagum. , 1994, Journal of natural products.

[31]  R. Muschel,et al.  The molecular basis for cell cycle delays following ionizing radiation: a review. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  S. Akinaga,et al.  Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C , 2004, Cancer Chemotherapy and Pharmacology.

[33]  A. Eastman,et al.  The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[34]  Scott Davey,et al.  Fission yeast chkl protein kinase links the rad checkpoint pathway to cdc2 , 1993, Nature.

[35]  A. Carr.  Checkpoints Take the Next Step , 1996, Science.

[36]  O'Connor Pm.  Mammalian G1 and G2 phase checkpoints. , 1997 .

[37]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[38]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.

[39]  S. Haggarty,et al.  High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. , 1998, Cancer research.

[40]  S. Carr,et al.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.

[41]  P. O'Connor.  Mammalian G1 and G2 phase checkpoints. , 1997, Cancer surveys.

[42]  P. Russell,et al.  Replication checkpoint enforced by kinases Cds1 and Chk1. , 1998, Science.

[43]  I. Radford,et al.  Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. , 1998, Cancer research.